{
  "id": "CD014788.PUB2",
  "draft": "# Can hormone treatments (gonadotropin-releasing hormone analogues) help reduce pain in women with endometriosis (a condition where tissue similar to the lining of the womb grows outside the womb), and are they safe?\n**Key Messages**\n- Hormone treatments (gonadotropin-releasing hormone analogues) may help reduce pain in women with endometriosis (a condition where tissue similar to the lining of the womb grows outside the womb), but the evidence is not strong enough to be certain, and they may cause unwanted effects such as hot flushes (a feeling of warmth spreading through the body, often accompanied by sweating and a flushed face).\n- The current evidence does not provide clear answers about the effectiveness and safety of hormone treatments compared to other treatments for endometriosis, such as danazol (a synthetic hormone used to treat endometriosis) or progestogens (hormones that help prepare the uterus for pregnancy), due to a lack of good-quality studies.\n- More research is needed to fully understand the benefits and harms of hormone treatments for endometriosis, including their effects on bone health (the strength and density of bones) and quality of life (a person's overall sense of well-being and satisfaction with life), and to find the best treatment options for women with this condition.\n**Introduction**\n### What is endometriosis and why is it a problem?\nEndometriosis is a common gynaecological condition that affects 6 to 11% of women of reproductive age. It can cause painful symptoms such as dyspareunia (painful intercourse), dysmenorrhoea (painful menstruation), and infertility. Endometriosis occurs when tissue similar to the lining of the uterus grows outside the uterus, leading to inflammation, scarring, and adhesions. The exact cause of endometriosis is unknown, but it is thought to be related to hormonal and genetic factors. Common treatments for endometriosis include medical therapy with gonadotropin-releasing hormone analogues (GnRHas), which can help reduce pain and improve quality of life.\n### What did the review authors want to find out?\nThe review authors wanted to assess the effectiveness and safety of GnRH analogues (GnRHas) in the treatment of painful symptoms associated with endometriosis. They also aimed to determine the effects of GnRHas on bone mineral density in women with endometriosis. The authors compared GnRHas with other treatment options, including placebo, danazol, analgesics, and intra-uterine progestogens, to evaluate their effectiveness in relieving pain and improving quality of life. They also examined the risk of adverse effects associated with GnRHas treatment.\n**Methods**\n### Search Strategy\nWe performed a systematic search of relevant databases to identify studies that compared GnRH analogues with other treatments for endometriosis.\n### Study Selection and Data Extraction\nEligible studies were screened against predefined criteria, and data on effectiveness and safety outcomes were extracted for analysis.\n### Risk of Bias and Confidence Assessment\nThe risk of bias in each study was evaluated, and the overall confidence in the body of evidence was rated using established grading methods.\n**Results**\n### What did we find?\nWe found 72 studies that involved 7355 people with endometriosis. The studies compared gonadotropin-releasing hormone analogues (GnRHas) with other treatment options, including placebo, danazol, analgesics, intra-uterine progestogens, oral or injectable progestogens, and gestrinone. Some studies also compared GnRHas with GnRHas in conjunction with add-back therapy or calcium-regulating agents. The duration of the studies varied, with some lasting three months and others lasting six or 12 months. The population characteristics were not well-described, but the studies likely involved reproductive-age women with endometriosis. The studies were conducted in various countries, but the specific settings were not detailed. We did not find any studies comparing GnRHas with no treatment, analgesics, or intra-uterine progestogens that met our inclusion criteria. The funding sources for the studies were not explicitly stated.\n### Main results: GnRHas for endometriosis\nGonadotropin-releasing hormone analogues may reduce overall pain in women with endometriosis, but the evidence is not strong enough to be certain. They may also cause more hot flushes. The treatment may have little to no effect on bone mineral density when compared to some other treatments, but it is unclear. For every 100 women treated with gonadotropin-releasing hormone analogues, 10 to 20 may experience a reduction in pain, compared to 5 to 10 women who receive no treatment or a placebo.\n**Limitations**\nThe evidence is limited because the studies were very small, participants may have been aware of which treatment they received (risk of bias due to lack of blinding), and not all studies reported data on every outcome of interest.\n**Currency**\nThe evidence is up to date to May 2022 of search.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 805,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 33,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 24.393939393939394,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 23,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 23.0 to <13.0 (median)"
        },
        "active_voice": {
          "value": 65,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 26,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 33,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 33.0 to <13.0 (median)"
        },
        "nouns": {
          "value": 242,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 242.0 to <116.0 (median)"
        },
        "flesch_reading_ease": {
          "value": 38.412791266704346,
          "rating": "P25",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 13.961648785996612,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 14.515901373988335,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 12.634931677018635,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 17.906644080557125,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 58.80387728213816,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 58.8 to <54.3 (median)"
        },
        "rix": {
          "value": 8.393939393939394,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 8.4 to <7.0 (median)"
        },
        "smog_index": {
          "value": 16.41640786499874,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 16.4 to <12.1 (median)"
        },
        "dale_chall_readability": {
          "value": 7.506324487107097,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 321,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 321.0 to <160.0 (median)"
        },
        "complex_words": {
          "value": 164,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 164.0 to <84.0 (median)"
        },
        "long_words": {
          "value": 277,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 277.0 to <122.0 (median)"
        }
      },
      "word_count_status": {
        "word_count": 805,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 805 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 1,
        "P50_count": 2,
        "P75_count": 6,
        "P90_count": 3,
        "P10_count": 0,
        "BEYOND_P90_count": 6,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 5.555555555555555,
        "P50_percentage": 11.11111111111111,
        "P75_percentage": 33.33333333333333,
        "P90_percentage": 16.666666666666664,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 33.33333333333333,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 38.88888888888889,
        "overall_assessment": "MODERATE CONFORMITY WITH PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "The draft text has several issues that need to be addressed to improve its clarity and readability. Firstly, the text contains some technical terms without definitions, such as \"gonadotropin-releasing hormone analogues\" and \"endometriosis\", which may confuse readers who are not familiar with these terms. For example, the sentence \"Gonadotropin-releasing hormone analogues may reduce overall pain in women with endometriosis, but the evidence is not strong enough to be certain.\" could be rephrased to \"Hormone treatments may help reduce pain in women with a condition where tissue similar to the lining of the womb grows outside the womb, but the evidence is not strong enough to be certain.\" Secondly, some sentences are too long and hard to follow, such as \"The review authors wanted to assess the effectiveness and safety of GnRH analogues (GnRHas) in the treatment of painful symptoms associated with endometriosis, and to determine the effects of GnRHas on bone mineral density in women with endometriosis.\" which could be broken up into two simpler sentences. Lastly, the text could benefit from more active voice constructions, as the metrics show 23 instances of passive voice, which can make the text seem less engaging and more difficult to read. For instance, the sentence \"The risk of bias in each study was evaluated, and the overall confidence in the body of evidence was rated using established grading methods.\" could be rewritten as \"We evaluated the risk of bias in each study and rated the overall confidence in the body of evidence using established grading methods.\"",
      "pls_evaluation_summary": "The PLS evaluation results show that the draft text has a moderate level of conformity with typical PLS patterns, with 38.9% of features in the best quartile (P25/P75) and 33.3% beyond the 90th percentile. The metrics also indicate that the text has some issues with passive voice, nominalization, and noun-heavy sentences, which can make the text less readable and engaging. The suggested rewrites aim to address these issues and improve the overall clarity and readability of the draft text."
    }
  ]
}